Navigation Links
Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/12/2009

POINT RICHMOND, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience, today announced financial results for the three and nine months ended September 30, 2009.

Transcept previously announced that on October 28, 2009, the FDA issued a Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. The NDA seeks approval to market Intermezzo® for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.

Glenn A. Oclassen, President and Chief Executive Officer commented, "Our focus is now on moving Intermezzo® forward through the remainder of the regulatory review process. With $93 million of cash, cash equivalents and marketable securities at September 30, 2009, we believe we have substantial resources on hand to cover a range of potential additional expenses that may be required to address the issues raised by the recent FDA Complete Response Letter. We expect to have more clarity on the FDA's remaining requirements for the Intermezzo® NDA after our planned meeting to discuss the Complete Response Letter. We are working with the FDA to schedule this meeting in early 2010."

"Purdue Pharma, our U.S. commercialization partner for Intermezzo®, has been actively engaged in our collaboration since we received the Complete Response Letter. We are working closely with the Purdue clinical, regulatory and packaging teams to address the concerns raised by FDA."

"With regard to other key Intermezzo® milestones, we announced last week that the United States Patent and Trademark Office issued a Notice of Allowance for one of our patent applications with claims that cover the use of our low-dose sublingual Intermezzo® formulation. Transcept is actively pursuing additional patents to protect Intermezzo® in the United States and key non-U.S. markets, and, as part of the NDA submission, has requested that the FDA grant three years of Hatch-Waxman marketing exclusivity to Intermezzo®."

Third Quarter 2009 Financial Results

Transcept recorded $2.08 million of revenue for the three month period ended September 30, 2009, related to recognition of a portion of the $25 million non-refundable license fee received from Purdue in connection with the signing of our collaboration agreement. Transcept plans to amortize the $25 million license fee over a 24 month period. There was no revenue for the three month period ended September 30, 2008.

Research and development expense for the quarter ended September 30, 2009 was approximately $2.14 million, compared to approximately $2.45 million for the same period in 2008. This decrease is primarily attributable to lower Intermezzo® development costs, the majority of which were incurred prior to the submission of the NDA in September 2008. The decrease was partially offset by severance expense incurred in connection with the reduction in force announced in August 2009. Research and development expense included non-cash stock compensation expense in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 718 Compensation - Stock Compensation ("ASC Topic 718") (formerly Statement of Financial Accounting Standards No. 123R (SFAS No. 123R)) of approximately $234,000 for the quarter ended September 30, 2009 and approximately $62,000 for the quarter ended September 30, 2008.

General and administrative expense for the quarter ended September 30, 2009 was approximately $3.84 million, compared to approximately $2.14 million for the same period in 2008. The $1.70 million increase consists primarily of higher professional fees to operate as a public company and to negotiate our collaboration with Purdue, increased personnel costs primarily in marketing and administration functions, an increase in operating expenses associated with additional office space and severance expense for the reduction in force noted above. General and administrative expense included non-cash stock compensation expense in accordance with ASC Topic 718 of approximately $299,000 for the quarter ended September 30, 2009, as compared to approximately $106,000 for the quarter ended September 30, 2008.

Net loss for the quarter ended September 30, 2009 was approximately $3.8 million or $0.29 per share (basic and diluted), compared to a net loss of approximately $4.3 million or $10.08 per share (basic and diluted) for the quarter ended September 30, 2008. The weighted average shares used to calculate basic and diluted net loss per share were 13,174,807 and 422,777 for the quarters ended September 30, 2009 and September 30, 2008, respectively. At September 30, 2009 there were 13,336,431 common shares outstanding and 1,984,385 outstanding options, warrants and common stock subject to repurchase.

Nine months ended September 30, 2009 Financial Results

Revenue for the nine months ended September 30, 2009 was $2.08 million related to recognition of a portion of the $25 million non-refundable license fee received from Purdue in connection with the signing of our collaboration agreement, compared to no revenue for the nine months ended September 30, 2008.

Research and development expense for the nine months ended September 30, 2009 was approximately $6.61 million, compared to approximately $8.84 million for the same period in 2008. The $2.23 million decrease is primarily attributable to lower Intermezzo® development costs, the majority of which were incurred prior to the submission of the Intermezzo® NDA on September 30, 2008. Research and development expense included non-cash stock compensation expense in accordance with ASC Topic 718 of approximately $391,000 for the nine months ended September 30, 2009 and approximately $192,000 for the nine months ended September 30, 2008.

General and administrative expense for the nine months ended September 30, 2009 was approximately $13.07 million, compared to approximately $5.37 million for the same period in 2008. The $7.70 million increase consists primarily of higher professional fees to operate as a public company and to negotiate our collaboration with Purdue, increased personnel costs primarily in marketing and administration, increased marketing expense as we prepared to commercialize Intermezzo® and an increase in operational expenses associated with additional office space. General and administrative expense included non-cash stock compensation expense in accordance with ASC Topic 718 of approximately $693,000 for the nine months ended September 30, 2009, as compared to approximately $268,000 for the nine months ended September 30, 2008.

Year-to-date merger-related transaction costs of approximately $2.22 million were expensed during the first quarter of 2009.

Net loss for the nine months ended September 30, 2009 was approximately $19.5 million or $1.65 per share, compared to a net loss of approximately $13.8 million or $35.93 per share for the nine months ended September 30, 2008. The weighted average shares used to calculate net loss per share were 11,764,652 and 385,214, respectively, for the nine months ended September 30, 2009 and 2008.

Cash, cash equivalents and marketable securities totaled $93.0 million at September 30, 2009.

Financial Guidance

Transcept believes it has substantial cash resources to cover a range of potential additional expenses that may be required to address the issues raised by the recent FDA Complete Response Letter on the Intermezzo® NDA.

General and administrative expense declined from approximately $5.02 million in the quarter ended June 30, 2009 to approximately $3.84 million in the quarter ended September 30, 2009. We anticipate that general and administrative expense will be closer to the lower end of this range during the fourth quarter of 2009 and the first half of 2010.

Research and development expense was approximately $2.25 million in the quarter ended June 30, 2009 and approximately $2.14 million in the quarter ended September 30, 2009. During the fourth quarter of 2009 and the first half of 2010, we anticipate:

  • Baseline research and development expense will remain substantially in line with these prior quarters;
  • Additional research and development expense of approximately $1.05 million will be incurred in connection with manufacturing activities undertaken in anticipation of the previously planned launch of Intermezzo® in 2010; and
  • Additional research and development expense will be incurred as Transcept determines and undertakes activities to support the planned resubmission of the Intermezzo® NDA.

Transcept is working with the FDA to schedule a meeting in early 2010, and plans to provide an update to investors as appropriate.

Conference Call and Webcast Information

Transcept will host a conference call and webcast on Thursday, November 12, 2009, at 5:00 p.m. Eastern time to discuss third quarter 2009 financial results. Telephone numbers for the live conference call are 877-874-1589 (U.S.) or 719-325-4805 (International). The webcast can be accessed on the Investors page of the Transcept website at www.transcept.com and will be available for replay until close of business on November 27, 2009. A playback of the call will be available through November 27, 2009 by dialing 888-203-1112 (U.S.) or 719-457-0820 (International), replay passcode: 2918743.

About Intermezzo®

Intermezzo® (zolpidem tartrate sublingual tablet), the lead product candidate at Transcept, has the potential to be the first prescription sleep aid specifically approved for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. Intermezzo® is a sublingual low dose formulation of zolpidem, the active agent most commonly prescribed in the United States for the treatment of insomnia. Intermezzo® uses approximately one-quarter to one-third of the dose of active drug contained in currently marketed zolpidem-based sleep aids, in a formulation designed to promote rapid sublingual absorption.

Two Phase 3 clinical studies evaluated 376 patients receiving either Intermezzo® or placebo. In the first study, a sleep laboratory trial using an objective polysomnographic endpoint, Intermezzo® demonstrated a statistically significant decrease versus placebo in the time it took patients to return to sleep as measured by Latency to Persistent Sleep. In the second study, an outpatient trial, Intermezzo® demonstrated a statistically significant decrease in Latency to Sleep Onset, a subjective patient reported endpoint. The most common adverse event seen in these trials was headache (2.7 percent active versus 1.4 percent placebo in the outpatient study).

In September 2008 Transcept submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009 Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. For further information, please visit the company's website at: www.transcept.com.

The United States Patent and Trademark Office granted a Notice of Allowance for claims that cover Intermezzo® under U.S. patent application no. 11/833,323. If issued, this patent will expire in 2025. Transcept is actively pursuing additional patents to protect Intermezzo® in the United States and key non-U.S. markets, and, as part of the NDA submission, has requested that the FDA grant three years of Hatch-Waxman marketing exclusivity to Intermezzo®.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. For further information, please visit the company's website at: www.transcept.com.

Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenues, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to expectations with respect to the following: the ability of Transcept to successfully obtain direction from the FDA that will effectively guide Transcept in support of its plans to resubmit the Intermezzo® NDA; the ability of Transcept to resubmit the Intermezzo® NDA to the FDA with sufficient data and other content to warrant FDA approval to market the drug candidate in its intended indication; the sufficiency of Transcept cash resources to cover a range of potential additional expenses that may be required to address the issues raised by the FDA Complete Response Letter; the potential approval and timing of regulatory decisions with respect to the NDA for Intermezzo®; Intermezzo® being the first commercially available sleep aid in the United States specifically approved for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep; the ability of Transcept to obtain and maintain patent protection and regulatory exclusivity for Intermezzo®; and financial guidance with respect to general and administrative expenses and research and development expenses. Transcept may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Transcept makes, including risks related to the following: the willingness and ability of the FDA to provide reliable guidance that will enable Transcept to make decisions in support of the Intermezzo® NDA; the ability of Transcept to design or successfully carry out additional safety studies in support of potential resubmission of an NDA for Intermezzo®; the sufficiency of the content in the planned resubmission in support of the Intermezzo® NDA; a decision by Purdue to not devote time or resources to support the approval of Intermezzo® or to terminate the Purdue collaboration agreement, even if the Intermezzo® NDA is approved; unforeseen expenses related to efforts in support of FDA approval, general and administrative expenses; other research and development expenses and the business of Transcept generally; dependence on third parties to manufacture Intermezzo®; obtaining, maintaining and protecting the intellectual property incorporated into Intermezzo®; other difficulties or delays in the commercialization of Intermezzo®; and the ability of Transcept to obtain additional funding, if needed, to support its business activities. These and other risks are described in greater detail in the "Risk Factors" section of Transcept periodic reports filed with the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments Transcept may enter into or make. Transcept does not assume any obligation to update any forward-looking statements, except as required by law.

FINANCIAL TABLES FOLLOW



    Transcept Pharmaceuticals, Inc.
    Statements of Operations
    (Unaudited)

                            Three Months Ended          Nine Months Ended
                               September 30,              September 30,
                            ------------------          -----------------
                             2009         2008          2009          2008
                             ----         ----          ----          ----
    Revenue:
      License fee
       revenue            $2,083,334        $-       $2,083,334         $-

    Operating expenses:
      Research and
       development         2,135,622    2,453,237     6,607,022     8,844,666
      General and
       administrative      3,839,612    2,141,535    13,072,734     5,365,574
      Merger related
       transaction costs           -         -        2,223,860          -
                                 ---       ---        ---------        ---
    Total operating
     expenses              5,975,234    4,594,772    21,903,616    14,210,240
                           ---------    ---------    ----------    ----------
    Loss from operations  (3,891,900)  (4,594,772)  (19,820,282)  (14,210,240)
    Interest income           54,729      133,878       239,661       682,117
    Interest expense          (4,176)    (176,060)     (175,100)     (618,188)
    Other income
     (expense), net           36,499      377,264       299,995       306,307
                              ------      -------       -------       -------
    Net loss             $(3,804,848) $(4,259,690) $(19,455,726) $(13,840,004)
                         ===========  ===========  ============  ============

    Basic and diluted
     net loss per share       $(0.29)     $(10.08)       $(1.65)      $(35.93)
                              ======      =======        ======       =======

    Weighted average
     shares outstanding   13,174,807      422,777    11,764,652       385,214
                          ==========      =======    ==========       =======




    Transcept Pharmaceuticals, Inc.
    Balance Sheets

                                  September 30,  December 31,
                                  -------------  ------------
                                       2009          2008
                                       ----          ----
    Assets                         (Unaudited)
    Current assets:
      Cash and cash equivalents     $10,729,594    $4,431,505
      Marketable securities          82,267,092     7,250,987
      Prepaid and other current
       assets                         1,714,064       381,836
      Restricted cash                   200,000       200,000
                                        -------       -------
    Total current assets             94,910,750    12,264,328
    Property and equipment, net       1,318,083     1,450,216
    Goodwill                          2,961,664             -
    Other assets                        826,243        65,970
                                        -------        ------
    Total assets                   $100,016,740   $13,780,514
                                   ============   ===========

    Liabilities, convertible
     preferred stock and
     stockholders' equity
     (net capital deficiency)
    Current liabilities:
      Accounts payable                 $605,529      $575,269
      Accrued liabilities             2,185,011     1,468,415
      Lease liability, short-
       term portion                     297,853             -
      Deferred revenue,  short-
       term portion                  12,500,000             -
      Loan payable, short-term
       portion                           43,908     3,347,010
                                         ------     ---------
    Total current liabilities        15,632,301     5,390,694
    Deferred revenue, long-term
     portion                         10,416,666             -
    Warrant liability                         -       599,845
    Deposit for stock purchase           51,780        87,656
    Deferred rent                       100,161        77,044
    Lease liability, long-term
     portion                            639,325             -
    Loan payable, long-term
     portion                            136,370       169,636
    Other liabilities                    12,500             -
                                         ------           ---
    Total liabilities                26,989,103     6,324,875
    Convertible preferred stock:
     $0.001 par value; 7,593,091
     shares authorized;
      0 shares issued and outstanding
      at September 30, 2009;
       Series A - 60,212, Series B -
       1,126,020, Series C - 2,838,091
       and Series D - 3,325,647 shares
       issued and outstanding at
       December 31, 2008                      -    71,036,951
    Stockholders' equity (net capital
     deficiency):
      Common stock, $0.001 par value;
       100,000,000 shares
       authorized; 13,336,431 and 454,676
       shares issued and outstanding
       at September 30, 2009 and
       December 31, 2008,
       respectively                      13,336           455
      Additional paid-in capital    157,516,702     1,503,841
      Accumulated deficit           (84,567,159)  (65,111,433)
      Accumulated other
       comprehensive income              64,758        25,825
                                         ------        ------
      Total stockholders' equity
       (net capital deficiency)      73,027,637   (63,581,312)
                                     ----------   -----------
    Total liabilities,
     convertible preferred stock
     and stockholders' equity
     (net capital deficiency)      $100,016,740   $13,780,514
                                   ============   ===========



    Contact:

    Transcept Pharmaceuticals, Inc.
    Greg Mann
    Director, Corporate Communications
    (510) 215-3567
    gmann@transcept.com

SOURCE Transcept Pharmaceuticals, Inc.


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine technology :

1. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
2. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
3. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
4. Transcept Pharmaceuticals to Report First Quarter 2009 Results
5. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
6. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
7. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
8. Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
9. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
10. Endo Pharmaceuticals and LecTec Settle Patent Dispute
11. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest laser ... the first of its kind in the area ... through advanced laser treatment. The physician-owned and operated ... Suncoast by storm with its revitalizing skin ... advanced multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
(Date:2/5/2016)... Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... agreement to acquire a majority ownership interest in Dental ... in Brazil . ... Dental Cremer is the dental distribution business of Cremer ...
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Edwards Lifesciences ... patient-focused innovations for structural heart disease and critical care ... accelerated share repurchase (ASR) agreement with Morgan Stanley & ... stock.  This repurchase is part of the Company,s previously ... the Company,s common stock.  --> ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... The event is being held on April 7, 2016 ... Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and ... Parkinson’s disease and is the architect of this informative event to raise awareness and ...
(Date:2/5/2016)... Dickson, Tennessee (PRWEB) , ... February 05, 2016 ... ... State Community College President George H. Van Allen have signed a joint enrollment ... semester, provides a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
(Date:2/5/2016)... ... ... Boar’s Head Brand®, one of the nation’s leading providers of premium delicatessen foods, ... out of your party preparation – follow these easy, yet delicious recipes with the ... , “The key to hosting a successful game-day party is creating a flavorful menu ...
(Date:2/5/2016)... ... ... Stuart Bentkover, MD, FACS is thrilled to announce the arrival of ... removal today, Dr. Bentkover is the only doctor in Central Massachusetts to offer patients ... approved by the Food and Drug Administration (FDA) as a safe and efficient method ...
Breaking Medicine News(10 mins):